HONG KONG, Aug. 26, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2021 interim results. 3SBio maintained strong performance in core businesses, with core products occupying a leading market share. Meanwhile, the Company continuously increased investments in research and development, while significantly accelerating its pipeline. In the future, 3SBio will reinforce its position as an industry leader by enhancing its competitive edges with further integration of R&D, manufacturing, commercialization and investment cooperation.